See more : Nan Nan Resources Enterprise Limited (1229.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Xeris Biopharma Holdings, Inc. (0A8E.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Xeris Biopharma Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Tang Palace (China) Holdings Limited (TNGPF) Income Statement Analysis – Financial Results
- Mizuno Corporation (8022.T) Income Statement Analysis – Financial Results
- Hiap Hoe Limited (5JK.SI) Income Statement Analysis – Financial Results
- Zhejiang Construction Investment Group Co.,Ltd (002761.SZ) Income Statement Analysis – Financial Results
- CyberAgent, Inc. (CYAGF) Income Statement Analysis – Financial Results
Xeris Biopharma Holdings, Inc. (0A8E.L)
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 163.91M | 110.25M | 110.25M | 49.59M | 20.16M | 2.47M | 1.56M | 1.08M |
| Cost of Revenue | 28.65M | 22.63M | 22.63M | 13.32M | 9.33M | 42.00K | 4.00K | 8.00K |
| Gross Profit | 135.27M | 87.61M | 87.61M | 36.27M | 10.83M | 2.42M | 1.55M | 1.07M |
| Gross Profit Ratio | 82.52% | 79.47% | 79.47% | 73.14% | 53.72% | 98.30% | 99.74% | 99.26% |
| Research & Development | 22.34M | 20.97M | 20.97M | 25.16M | 20.92M | 40.65M | 20.17M | 10.24M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 21.11M | 8.02M | 4.06M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 146.10M | 137.75M | 137.75M | 125.72M | 73.73M | 21.11M | 8.02M | 4.06M |
| Other Expenses | 10.84M | -14.14M | 10.84M | 550.00K | -280.00K | 0.00 | -1.00K | -5.00K |
| Operating Expenses | 168.44M | 169.55M | 169.55M | 151.43M | 94.37M | 61.77M | 28.18M | 14.30M |
| Cost & Expenses | 207.92M | 192.19M | 192.19M | 164.75M | 103.70M | 61.81M | 28.19M | 14.31M |
| Interest Income | 4.75M | 2.58M | 2.58M | 313.00K | 2.97M | 1.61M | 124.00K | 5.00K |
| Interest Expense | 26.61M | 15.33M | 15.33M | 7.18M | 10.66M | 2.55M | 2.00K | 2.00K |
| Depreciation & Amortization | 13.16M | 12.67M | 1.88M | 1.47M | 1.08M | 320.00K | 177.00K | 116.00K |
| EBITDA | -23.74M | -69.31M | -113.67M | -80.08M | -117.80M | -57.22M | -26.38M | -13.09M |
| EBITDA Ratio | -14.48% | -64.49% | -64.49% | -231.11% | -399.81% | -2,342.03% | -1,692.10% | -1,220.00% |
| Operating Income | -44.01M | -81.94M | -81.94M | -115.16M | -83.55M | -59.34M | -26.63M | -13.23M |
| Operating Income Ratio | -26.85% | -74.32% | -74.32% | -232.22% | -414.52% | -2,407.46% | -1,711.38% | -1,230.79% |
| Total Other Income/Expenses | -19.49M | -14.14M | -7.57M | -7.70M | -3.66M | -736.00K | 75.00K | 22.00K |
| Income Before Tax | -63.50M | -96.08M | -96.08M | -122.73M | -91.25M | -60.08M | -26.55M | -13.21M |
| Income Before Tax Ratio | -38.74% | -87.15% | -87.15% | -247.48% | -452.74% | -2,437.32% | -1,706.56% | -1,228.74% |
| Income Tax Expense | -1.25M | -1.42M | -1.42M | -110.00K | -110.00K | 1.81M | 1.00K | -3.00K |
| Net Income | -62.26M | -94.66M | -94.66M | -122.73M | -91.14M | -60.08M | -26.55M | -13.21M |
| Net Income Ratio | -37.98% | -85.86% | -85.86% | -247.48% | -452.20% | -2,437.32% | -1,706.56% | -1,228.74% |
| EPS | -0.45 | -0.70 | -1.20 | -2.88 | -3.49 | -4.99 | -13.09 | -7.17 |
| EPS Diluted | -0.45 | -0.70 | -1.20 | -2.88 | -3.49 | -4.99 | -13.09 | -7.17 |
| Weighted Avg Shares Out | 137.67M | 135.63M | 79.03M | 42.64M | 26.11M | 12.05M | 2.03M | 1.84M |
| Weighted Avg Shares Out (Dil) | 137.67M | 135.63M | 79.03M | 42.64M | 26.11M | 12.05M | 2.03M | 1.84M |
Source: https://incomestatements.info
Category: Stock Reports